Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

被引：0
|
作者：
Cobain, Erin F. [1 ]
Hayes, Daniel F. [1 ]
机构：
[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 32期
关键词：
PATIENT-LEVEL METAANALYSIS; RIBOCICLIB PLUS FULVESTRANT; CELL-FREE DNA; POSTMENOPAUSAL WOMEN; MUTATIONS; LETROZOLE; SURVIVAL; TRIAL; MULTICENTER; PALBOCICLIB;
D O I：
10.1200/JCO.22.00702
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：3673 / +
页数：5
相关论文
共 50 条
  • [21] Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy
    Masahiro Ito
    Masakazu Amari
    Akiko Sato
    Masahiro Hikichi
    Natsuko Tsurumi
    Hinano Otofuji
    Shigehira Saji
    Breast Cancer Research and Treatment, 2025, 209 (3) : 503 - 512
  • [22] Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer
    Nahleh, ZA
    Jazieh, AR
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 631 - 633
  • [23] Factors That Predict Biological Aggressiveness in Estrogen Receptor-Positive / Human Epidermal Growth Factor Receptor 2-Negative / Lymph Node-Negative Breast Cancer
    Arthur, Lauren E.
    McMann, Ashley H.
    Slattery, Lauren N.
    Fuhrman, George M.
    Mackey, Aimee M.
    Rivere, Amy E.
    Corsetti, Ralph L.
    OCHSNER JOURNAL, 2020, 20 (04): : 381 - 387
  • [24] Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
    Al-Foheidi, Meteb H.
    Albeshri, Asem Mohammed
    Moamenkahan, Safwan Noor
    Abdullah, Abdulmajid Mohammed
    Abualola, Muhannad Sadaqa
    Alharbi, Muath Hamed
    Refa, Ahmed A.
    Bayer, Ali M.
    Shaheen, Ahmed Y.
    Aga, Syed Sameer
    Khan, Muhammad Anwar
    Al-Mansour, Mubarak M.
    Ibrahim, Ezzeldin M.
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 17 (01)
  • [25] Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer
    O'Keefe, Kaitlyn
    Desai, Neelam, V
    Tan, Antoinette R.
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 517 - 527
  • [26] Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review
    Li, Junjie
    Wang, Zhonghua
    Shao, Zhimin
    CANCER MEDICINE, 2019, 8 (05): : 1943 - 1957
  • [27] Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
    Pusztai, Lajos
    Kalashnikova, Ekaterina
    Hobbs, Evthokia
    Brown-Glaberman, Ursa
    Mita, Monica
    Klein, Paula
    Yan, Fengting
    Ehsani, Sima
    Razaq, Wajeeha
    Stopeck, Alison
    Bhave, Manali
    Loch, Michelle
    Sardesai, Sagar
    Torres, Evanthia Roussos
    Burkard, Mark
    Okubanjo, Femi
    Gauthier, Eric
    Rodriguez, Angel
    Liu, Minetta
    Kabos, Peter
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
    Tan, Aihua
    Nong, Li
    Wang, Hongxue
    Jia, Yuxian
    Zhong, Wuning
    Qin, Fanghui
    Wang, Han
    Tang, Jing
    Liu, Yan
    Lu, Yongkui
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [29] Expanding Treatment Arsenal for Oestrogen Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Sze, H.
    HONG KONG JOURNAL OF RADIOLOGY, 2019, 22 (02): : 86 - 97
  • [30] Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Brufsky, Adam M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2015, 9 : 137 - 147
12345